Cancer of the prostrate is common in men after they attain a certain age. One of the best known methods for treating the prostate cancer is ADT or Androgen deprivation therapy which blocks the male hormone thereby preventing the cancerous cells of the prostate to thrive with its aid.
A new research study has now revealed that the ADT might be responsible for bone decay too. A group of researchers associated with the University of Melbourne, Australia state that the study is the first one to take a look at the bone structure during the course of ADT therapy. About 20% to 50% of all men diagnosed with prostate cancer are usually put on the therapy. The study is due to be published by the Journal of Clinical Endocrinology & Metabolism which is brought out by the Endocrine Society.
The study involved observing 26 men who were undergoing the therapy. They were kept under observation for a period of one year by the researchers. The lead author of the study, Dr. Emma Hamilton, said in a press release that they had taken the help of a new technology that could assess the micro-architecture of the bone structure. The findings showed a decay of both the cortical or the outer hard shell as well as the trabecular which is the inner spongy mesh of the bone.
This particular study comes just after similar findings were reported by the University Health Network, Toronto. The Canadian study included 19,079 men, all over the age of 55 who had been put on the ADT therapy. These men were compared to others of similar age and medical conditions but not on the therapy. The men were watched for over six years when the researchers found out that there had been a 45% increase in fractures among men who had been on the hormone therapy vis-à-vis the men who were not.